Trial Profile
Body Composition Sub-study of the D2EFT Trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 27 Jul 2023
Price :
$35
*
At a glance
- Drugs Darunavir (Primary) ; Dolutegravir (Primary) ; Emtricitabine (Primary) ; Lamivudine (Primary) ; Ritonavir (Primary) ; Tenofovir disoproxil fumarate (Primary) ; Nucleotide reverse transcriptase inhibitors
- Indications HIV infections
- Focus Pharmacodynamics
- Acronyms D2EFT
- 24 Jul 2023 Planned primary completion date changed from 15 Jan 2023 to 15 Jan 2024.
- 22 Nov 2022 Status changed from recruiting to active, no longer recruiting.
- 30 Aug 2021 Planned End Date changed from 15 Jan 2022 to 15 Jan 2024.